Stopping a GLP-1? Make the plan before the last dose

Will I regain weight if I stop Ozempic or another GLP-1?

Many people regain some weight after a GLP-1–based medicine is stopped. Not everyone regains everything, and no trial can tell you exactly what your body will do.

For many people, appetite and weight begin moving back after treatment stops. That is not proof of weak willpower. It is why maintenance belongs in the plan before the last dose—not after it.

What happened when people stopped the medicine?

In an extension of the STEP 1 weight-management trial, participants had used semaglutide 2.4 mg. They regained about two-thirds of the weight they had lost during the year after the medicine and the trial’s structured lifestyle support ended. They did not regain everything on average: the group was still about 5.6% below its starting weight. Several blood-pressure, blood-sugar, cholesterol, and inflammation improvements moved back toward where they had begun.

STEP 4 asked a slightly different question using semaglutide at the same 2.4 mg dose. People assigned to stop gained an average 6.9% of body weight over the next 48 weeks while lifestyle counseling continued; people assigned to stay on treatment lost more. This shows that regain can happen even when someone is still receiving lifestyle support.

In SURMOUNT-4, participants had reached their maximum tolerated dose of 10 or 15 mg of tirzepatide—a medicine that acts on both GIP and GLP-1. Those assigned to stop gained an average 14% of their week-36 body weight over the following year. They still remained about 9.9% below their original starting weight on average. People who continued treatment lost more.

Why stopping is not a willpower test

These medicines change biological signals involved in hunger, fullness, blood sugar, and food intake while they are being used. Some people notice hunger or food thoughts becoming louder as the effect fades. The trials cannot predict exactly when—or how strongly—that will happen for you.

Weight returning after treatment ends is not evidence of addiction and, by itself, is not a drug-withdrawal syndrome. The medicine’s effects on appetite and weight regulation can fade after treatment stops.

The reason the medicine was prescribed matters too. A person taking it for type 2 diabetes, heart-risk reduction, kidney disease, or another approved reason may need a new plan for more than weight. Stopping should never be treated as a scale-only decision.

What the numbers mean—and what they do not mean

Group averages cannot predict your result.

The main studies of stopping treatment included adults with overweight or obesity who did not have diabetes. Some included only people who had already been able to take the medicine and had responded to it. The results cannot tell us what happens with every condition, dose, product, length of treatment, or person. The medicine manufacturers funded these studies.

The studies tracked weight and risk factors after stopping. They were not designed to establish how stopping affects heart-attack or stroke risk, and they do not show that every health benefit disappears. They support discussing a maintenance plan with your prescriber.

Build the stopping plan before the last dose

There is no one proven taper, food plan, workout, or maintenance dose that fits everyone. Do not improvise a taper, change the schedule, or restart an old dose after a long gap without the prescriber. The safest plan depends on the exact medicine, why it was prescribed, side effects, other conditions, cost, pregnancy plans, and what changed while you were taking it.

Food, strength work, sleep, and regular activity can support your health and what your body can do. They cannot guarantee that weight will stay off. We are still learning what helps people keep weight off after stopping a GLP-1 medicine.

Bring notes about changes in your blood pressure, blood sugar, cholesterol, sleep, symptoms and strength, as well as your weight and waist measurement.

The HEART RESERVE takeaway

Before stopping, agree with your prescriber on what you will monitor, when you will follow up, and what to do if weight, blood sugar, symptoms, or other health concerns change.